Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings
about
Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countriesEvidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA TrialHIV-1 drug resistance and resistance testing.Drug susceptibility and resistance mutations after first-line failure in resource limited settingsDurability of antiretroviral therapy and predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up.Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa.HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir.Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational databaseLopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230Assessment of non-standard HIV antiretroviral therapy regimens at Lighthouse Trust in Lilongwe, MalawiEvaluation of WHO immunologic criteria for treatment failure: implications for detection of virologic failure, evolution of drug resistance and choice of second-line therapy in IndiaEmergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settingsAre subtype differences important in HIV drug resistance?Challenges of Maintaining Good Clinical Laboratory Practices in Low-Resource Settings: A Health Program Evaluation Framework Case Study From East Africa.Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genesLong-term outcome of second-line antiretroviral therapy in resource-limited settings.Ritonavir-boosted lopinavir as maintenance monotherapy in HIV-infected patients who achieved viral suppression during a second-line protease inhibitor-based regimen: a pilot randomized trial (BIDI-MONO).High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009-2014.HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
P2860
Q27001286-85473316-69F2-42F3-BB51-2D6335E31EF2Q28548288-B266F6FA-B578-442B-95A0-25215017E969Q30245693-5B6C4222-8711-4A66-84D3-B0E067DA3C50Q34106181-5A0E4E8F-2812-4C48-BC94-79A352BA9EEBQ34475728-B79CEF05-6281-4F7D-AC0A-E96774351216Q34625910-477F139E-BE43-4C7C-A001-E26B7803DBC3Q34710691-0CC89045-C426-4A56-A57F-ACE496A231D2Q34977431-3BC9FDA7-38B4-48C0-93A8-2C74830EDC4DQ35588154-AD2E20D5-38A2-4E87-866A-F282B87E8F0FQ36893580-A373B3E0-B606-48CA-9937-090A47984D90Q36902291-9A3C7DC0-13B6-4199-87B9-D5777719F487Q37003942-EA7FC5D8-D11D-406A-8171-592730BC481AQ37633109-FC43E1B5-382D-4CEF-8152-5F95B65261DEQ39544239-5CD06F68-4EFA-4C78-8BF1-1B6794528531Q40507125-56341973-8B9A-43A7-86CE-1A28697FBA03Q42174237-DC03A6F1-AAEA-4146-BDC4-21CC5DA039E3Q42229109-A2BB6E2B-31AE-4FA3-A14E-6C5167235E97Q42246085-764B517D-7105-483F-8F28-8E810CA28657Q42649793-0A18D766-344B-4FEE-A69A-5926B2AB748AQ44248029-C359463F-5C31-4732-B533-952E6A522EF7
P2860
Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Lopinavir/ritonavir monotherap ...... y in resource-limited settings
@ast
Lopinavir/ritonavir monotherap ...... y in resource-limited settings
@en
type
label
Lopinavir/ritonavir monotherap ...... y in resource-limited settings
@ast
Lopinavir/ritonavir monotherap ...... y in resource-limited settings
@en
prefLabel
Lopinavir/ritonavir monotherap ...... y in resource-limited settings
@ast
Lopinavir/ritonavir monotherap ...... y in resource-limited settings
@en
P2093
P2860
P1433
P1476
Lopinavir/ritonavir monotherap ...... y in resource-limited settings
@en
P2093
Beatrice A Kallungal
Carole L Wallis
David A Katzenstein
Evgenia Aga
Heather J Ribaudo
John A Bartlett
John A Crump
Karin L Klingman
Khuanchai Supparatpinyo
Michael R Norton
P2860
P304
P356
10.1097/QAD.0B013E328353B066
P407
P577
2012-07-01T00:00:00Z